| Date | Time | Source | Announcement |
|---|---|---|---|
| 01 Dec 2017 | 07:05 AM | Notification of first patent grant | |
| 09 Nov 2017 | 07:00 AM | SkinBiotix platform passes external toxicity tests | |
| 08 Nov 2017 | 11:32 AM | SkinBioTherapeutics to present at investor evening | |
| 30 Oct 2017 | 11:23 AM | Result of AGM | |
| 05 Oct 2017 | 07:00 AM | Final Results | |
| 03 Oct 2017 | 07:00 AM | Cytotoxicity results and scientific update | |
| 27 Sep 2017 | 09:00 AM | Notice of Results | |
| 12 Sep 2017 | 08:54 AM | Holding(s) in Company | |
| 19 Jun 2017 | 09:00 AM | SkinBioTherapeutics to Present at Investor Evening | |
| 09 Jun 2017 | 10:38 AM | Holding(s) in Company | |
| 23 May 2017 | 03:21 PM | Holding(s) in Company | |
| 23 May 2017 | 07:00 AM | Extension of Research Contract | |
| 05 Apr 2017 | 07:00 AM | First day of dealings - to trade under SBTX ticker |
SkinBioTherapeutics is a life science company that develops technologies to improve health by harnessing the human microbiome.
SkinBioTherapeutics is based in Newcastle upon Tyne, United Kingdom.
SkinBioTherapeutics is listed in London under the ticker SBTX.
SBTX share price listed at 16p in 2017.